Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04880434
Title Study to Evaluate the Efficacy of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3) (ZUMA-2)
Acronym ZUMA-2
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Kite, A Gilead Company
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | NLD | GBR | FRA | ESP | DEU


No variant requirements are available.